Valeant Pharmaceuticals Intl Inc (TSE:VRX)‘s stock had its “sector perform” rating reaffirmed by investment analysts at Royal Bank Of Canada in a report released on Tuesday.

Other equities analysts have also issued reports about the company. TD Securities decreased their price objective on Valeant Pharmaceuticals Intl from C$45.00 to C$38.00 in a report on Wednesday, June 8th. Scotiabank cut their target price on Valeant Pharmaceuticals Intl from C$35.00 to C$32.00 and set a “sector perform” rating for the company in a research report on Monday, July 25th. Three research analysts have rated the stock with a hold rating and two have given a buy rating to the stock. Valeant Pharmaceuticals Intl currently has an average rating of “Hold” and a consensus target price of C$38.83.

Valeant Pharmaceuticals Intl (TSE:VRX) opened at 35.82 on Tuesday. The stock’s market cap is $12.45 billion. Valeant Pharmaceuticals Intl has a 52-week low of $24.32 and a 52-week high of $299.06. The firm’s 50-day moving average price is $36.04 and its 200 day moving average price is $38.29.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at

Valeant Pharmaceuticals Intl Company Profile

Valeant Pharmaceuticals International, Inc is a specialty pharmaceutical and medical device company. The Company is engaged in developing, manufacturing, and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices), which are marketed directly or indirectly in over 100 countries.

Receive News & Ratings for Valeant Pharmaceuticals Intl Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals Intl Inc and related companies with's FREE daily email newsletter.